|
Synonyms: Andexxa® | coagulation factor Xa (recombinant), inactivated-zhzo | Ondexxya® | PRT064445 | PRT4445 | r-antidote
andexanet alfa is an approved drug (FDA (2018), EMA (2019))
Compound class:
Peptide or derivative
Comment: Andexanet alfa is a recombinant modified human Factor Xa (FXa) protein that acts as a mimetic of endogenous human factor Xa, and which was developed as a universal antidote to reverse thhe anticoagulant effects of direct or indirect FXa inhibitors. Information regarding the invention of andexanet alfa is available in patent WO2009042962 [2].
View more information in the IUPHAR Pharmacology Education Project: andexanet alfa |
Classification  |
|
| Compound class | Peptide or derivative |
| Approved drug? | Yes (FDA (2018), EMA (2019)) |
| International Nonproprietary Names |
|
| INN number | INN |
| 9883 | andexanet alfa |
| Synonyms |
| Andexxa® | coagulation factor Xa (recombinant), inactivated-zhzo | Ondexxya® | PRT064445 | PRT4445 | r-antidote |
| Database Links |
|
| GtoPdb PubChem SID | 223365912 |
| Search PubMed clinical trials | andexanet alfa |
| Search PubMed titles | andexanet alfa |
| Search PubMed titles/abstracts | andexanet alfa |
| UniParc | UPI0001AD5DCA |
| Wikipedia | Andexanet_alfa |
